PDCD1 and non-small cell lung carcinoma: Drugs such as pembrolizumab and nivolumab which block programmed cell death protein 1 (PD-1), a T cell expressed receptor, have been successfully used in patients with metastatic NSCLC with high PD-L1 expression and have demonstrated increased survival rates.